Stock CALA CALITHERA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Calithera Biosciences, Inc. Share Price

Equities

CALA

US13089P5070

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 07:00:40 26/04/2024 pm IST 		5-day change 1st Jan Change
0.02 USD 0.00% Intraday chart for Calithera Biosciences, Inc. -20.32% -33.33%
2023 Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease CI
2023 North American Morning Briefing : Stock Futures -2- DJ

Financials

Sales 2021 9.75M 813M Sales 2022 - Capitalization 15.86M 1.32B
Net income 2021 -115M -9.59B Net income 2022 -39M -3.25B EV / Sales 2021 -0.68 x
Net cash position 2021 56.5M 4.71B Net cash position 2022 23.78M 1.98B EV / Sales 2022 -
P/E ratio 2021
-0.43 x
P/E ratio 2022
-0.41 x
Employees 9
Yield 2021 *
-
Yield 2022
-
Free-Float 98.93%
More Fundamentals * Assessed data

Chart Calithera Biosciences, Inc.

Dynamic Chart

Latest news about Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Retail Sales, -2- DJ
Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Calithera Biosciences, Inc. Auditor Raises 'Going Concern' Doubt CI
Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from S&P TMI Index CI
Calithera Biosciences, Inc.(NasdaqGS:CALA) dropped from NASDAQ Composite Index CI
Top Premarket Decliners MT
Calithera Biosciences Shares Set to be Suspended From Nasdaq on Feb. 2; Stock Declines Premarket MT
Top Midday Decliners MT
Calithera Biosciences to Proceed With Liquidation and Dissolution of Company MT
Calithera Biosciences, Inc. Announces Departure of Susan M. Molineaux as Chief Executive Officer CI
Calithera Biosciences, Inc. Announces Departure of Stephanie Wong as Chief Financial Officer CI
Calithera Biosciences, Inc. Announces Executive Departures CI
Antengene Signs Assignment Deal with Calithera to Acquire Rights on Cancer Tumor Drug; Shares Climb 10% MT
More news

Analyst Recommendations on Calithera Biosciences, Inc.

Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral From Buy MT
SVB Securities Downgrades Calithera Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $18 MT
HC Wainwright Upgrades Calithera Biosciences to Buy From Neutral; Price Target is $8 MT
SVB Leerink Adjusts Calithera Biosciences' Price Target to $2 from $3, Keeps Outperform Rating MT
Ladenburg Thalmann Starts Calithera Biosciences at Buy with $4 Price Target MT
More recommendations

Press releases Calithera Biosciences, Inc.

CALITHERA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) AQ
CALITHERA BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) AQ
Calithera Biosciences Announces Board Approval of Complete Liquidation and Dissolution AQ
Calithera: Q3 Earnings Snapshot AQ
CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) AQ
More press releases

News in other languages on Calithera Biosciences, Inc.

Apple : Les valeurs à suivre sur les marchés américains
More news

Quotes and Performance

1 week-20.32%
Current month-18.70%
3 months-33.33%
6 months-33.33%
Current year-33.33%
More quotes

Highs and lows

1 week
0.02
Extreme 0.02
0.03
1 month
0.02
Extreme 0.02
0.05
Current year
0.02
Extreme 0.02
0.12
1 year
0.01
Extreme 0.01
0.50
3 years
0.01
Extreme 0.01
51.85
5 years
0.01
Extreme 0.01
163.60
10 years
0.01
Extreme 0.01
669.60
More quotes

Managers and Directors - Calithera Biosciences, Inc.

Managers TitleAgeSince
Susan Molineaux FOU
 Founder 70 09/10/09
Stephanie Wong DFI
 Director of Finance/CFO 50 01/14/01
Keith Orford BRD
 Director/Board Member 52 01/15/01
Members of the board TitleAgeSince
J. Garland BRD
 Director/Board Member 55 10/20/10
Henry Ward Wolff BRD
 Director/Board Member 75 02/14/02
Deepa Pakianathan BRD
 Director/Board Member 59 01/12/01
More insiders

Quotes

Date Price Change Volume
26/24/26 0.02 0.00% 261
24/24/24 0.02 -31.03% 191
23/24/23 0.029 +15.77% 583
18/24/18 0.025 -37.38% 1,075

Delayed Quote OTC Markets, April 26, 2024 at 07:00 pm IST

More quotes

Company Profile

Calithera Biosciences, Inc. is a shell company. The Company is winding up its operations. The Company is seeking to sell all of its clinical assets and programs. The Company has not generated any revenue.
Sector
Pharmaceuticals
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CALITHERA BIOSCIENCES, INC. Stock Calithera Biosciences, Inc.
-33.33% 97.45K
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CALA Stock